# Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

> **NCT01300988** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 18 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Aprepitant
- **DRUG:** Aprepitant placebo

## Key facts

- **NCT ID:** NCT01300988
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300988, "Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01300988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*